Virus du papillome humain

206,000 more girls to benefit from HPV vaccine with GAVI Alliance support

An estimated 206,000 girls in 10 developing countries are expected to benefit from the introduction of human papillomavirus (HPV) vaccine, which protects against the leading cause of cervical cancer, announced the GAVI Alliance on World Cancer Day.
The latest round of approved HPV vaccine introductions will see 10 countries begin targeted demonstration projects. The new approvals bring the total number of countries lined up to receive GAVI support for HPV vaccine to 21.

MMR vaccine linked to fall in respiratory-related hospitalizations Read more: MMR vaccine linked to fall in respiratory-related hospitalizations

Investigations into the unintended effects of vaccines tend to focus on potential adverse events, but some studies in low-income countries have shown that widespread immunization can cause unexpected positive consequences. A Danish team has now generated evidence that some of these unintended benefits are seen in wealthy countries, too.


This year, the doctors are going to provide coverage of at least 97% of a contingent with preventive vaccinations, according to the national immunization schedule. This will ensure the country's epidemiological wellbeing on infections, the spread of which can be successfully controlled through vaccination.

Read more.


President's Cancer Panel Issues Urgent Call to Action to Increase HPV Vaccination Read more: President's Cancer Panel Issues Urgent Call to Action to Increase HPV Vaccination

Achieving widespread HPV (human papillomavirus) vaccination is one of the most profound opportunities for cancer prevention, according to a report released today by the President's Cancer Panel. The Panel's report, Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer, issues an urgent call for energizing efforts to reach the HPV vaccines' potential to save lives and prevent millions of avoidable cancers and HPV-related conditions in men and women.


Virus-like particles (VLPs) as vaccines, vectors and adjuvants Conference

Hosted by Fondation-Merieux.

From the Fondation-Merieux website: 

Vaccines are playing a major role in reducing the impact of infectious diseases. Nevertheless, vaccines have still to target important health problems. The development of individual viral proteins as vaccine candidates has met a limited success although these viral proteins were the targets of neutralizing antibodies mediating protection.

Alternative approaches are needed, and virus-like particles (VLPs) could contribute to progress in this regard.


CDC Publishes 2014 Immunization Schedule

The Center for Disease Control and Prevention (CDC) have released their updated vaccination recommendations for adults of 19 years and above, having been approved back in October by a series of associations -including the Advisory Committee on Immunization, American Academy of Family Physicians, and the American College of Nurse-Midwives.


CDC names HVP 4th biggest threat to US health in 2014

The debate surrounding the Human papillomavirus (HPV) has been around for years, and the US Center for Disease Control and Prevention (CDC) has named HPV the 4th largest health threat the US will face in 2014. So how can authorities increase the number of people vaccinated above the mere 34.8% of girls between the ages of 13 and 17 who had actually completed the three-dose course?

Nanoparticle vaccine offers better protection

Many viruses and bacteria infect humans through mucosal surfaces, such as those in the lungs, gastrointestinal tract and reproductive tract.


Girls to be immunized against cervical cancer

After two years of a successful pilot, the stage is set for the implementation of a massive cervical cancer vaccination exercise in which young girls aged 9- 15 years old throughout the country will be vaccinated against the deadly disease. 
According to Dr. Robert Mayanja, the Uganda National Expanded Programme on Immunization (UNEPI)   programme manager, plans to start the exercise are in high gear.

‘Remote-controlled’ vaccine delivery could eliminate need for booster jabs

Many vaccines, such as those for Hep A and B, HPV, MMR and rabies, need several booster doses to achieve maximal immunological protection. Booster doses add to the complexity of vaccine administration, especially when used in large vaccination campaigns in the developing world.